{"entity":{"id":"emsy","kind":"target","name":"EMSY","aka":["EMSY transcriptional repressor, BRCA2 interacting","BRCA2-interacting transcriptional repressor EMSY","C11orf30"],"tldr":"EMSY (BRCA2-interacting transcriptional repressor EMSY) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","summary":"Regulator which is able to repress transcription, possibly via its interaction with a multiprotein chromatin remodeling complex that modifies the chromatin. Its interaction with BRCA2 suggests that it may play a central role in the DNA repair function of BRCA2. Mediates ligand-dependent transcriptional activation by nuclear hormone receptors.\n\nCIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Bevacizumab, Paclitaxel, Carboplatin and Talazoparib.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:18071","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18071"},{"label":"UniProt Q7Z589","url":"https://www.uniprot.org/uniprotkb/Q7Z589/entry"},{"label":"NCBI Gene 56946","url":"https://www.ncbi.nlm.nih.gov/gene/56946"},{"label":"Ensembl ENSG00000158636","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158636"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; CIViC holds 2 clinical evidence items on its variants; UniProt keyword \"DNA repair\". Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Acral Lentiginous Melanoma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"EMSY","role":["drug-target","biomarker","dna-repair"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:18071","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18071","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q7Z589","url":"https://www.uniprot.org/uniprotkb/Q7Z589/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene EMSY","url":"https://civicdb.org/features/13556","note":"2 evidence items, 0 assertions, 2 variants; diseases: Ovarian Serous Carcinoma, Acral Lentiginous Melanoma (GraphQL API, CC0)"}],"hgnc":"HGNC:18071","ensembl":"ENSG00000158636","uniprot":"Q7Z589","entrez":"56946","biology":"Regulator which is able to repress transcription, possibly via its interaction with a multiprotein chromatin remodeling complex that modifies the chromatin. Its interaction with BRCA2 suggests that it may play a central role in the DNA repair function of BRCA2. Mediates ligand-dependent transcriptional activation by nuclear hormone receptors. Location: Nucleus (UniProt). Locus 11q13.5 (HGNC).","whereFound":["Ovarian cancer: CIViC evidence names this disease"],"targetClass":"transcription","prevalence":[]},"route":"/targets/emsy/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}]}}